Holen Sie sich die Stockscreener-App
77.99
0.66%
0.51
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics CMO sells $1.45 million in shares By Investing.com - Investing.com Canada
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView — Track All Markets
Apogee Therapeutics price target raised to $133 from $95 at Stifel - MSN
What technical signals suggest for Apogee Therapeutics Inc. stockTrade Exit Report & Weekly Hot Stock Watchlists - ulpravda.ru
Can Apogee Therapeutics Inc. stock weather global recessionJuly 2025 Summary & Verified Technical Trade Signals - ulpravda.ru
Levels Update: How Apogee Therapeutics Inc. stock reacts to job market data2025 Market Trends & Fast Gaining Stock Strategy Reports - ulpravda.ru
Apogee Therapeutics (APGE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
What insider trading reveals about Apogee Therapeutics Inc. stock2025 Winners & Losers & Verified Momentum Stock Alerts - ulpravda.ru
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com South Africa
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation - Nasdaq
Will Apogee Therapeutics Inc. stock gain from lower inflationMarket Profile Overview & High Yield Portfolio Picks - ulpravda.ru
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data - Investing.com Nigeria
March 20th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
Will Apogee Therapeutics Inc. stock benefit from AI adoptionBreakout Stock Watch & Secret Picks Wall Street Isn’t Talking About - ulpravda.ru
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Apogee Therapeutics CFO Sells 8,000 Shares - TradingView — Track All Markets
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating - Investing.com Nigeria
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com Australia
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data By Investing.com - Investing.com South Africa
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com Nigeria
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com India
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics to report interim asthma trial results By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Interim Results for Zumilokibart (APG777) in Mild-to-Moderate Asthma and Highlights 2026 Development Milestones - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - Chartmill
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - Sahm
Apogee Therapeutics to report interim asthma trial results - Investing.com India
User - FinancialContent
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00 - MarketBeat
(APGE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis Report | Financials & Insights - Benzinga
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Apogee Therapeutics Earnings Notes - Trefis
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com Australia
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):